Business Context and Reporting Period
Company: Accuray Incorporated (ARAY)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 2026
Business Overview: Accuray designs, develops, and sells advanced radiosurgery and radiation therapy systems (CyberKnife and TomoTherapy platforms) for cancer treatment. The company operates globally with significant exposure to international markets, particularly China via a joint venture.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2026 | Nine Months Ended Mar 31, 2026 | Three Months Ended Mar 31, 2025 | Nine Months Ended Mar 31, 2025 |
|---|---|---|---|---|
| Net Revenue | $104.8 million | $301.0 million | $113.2 million | $331.0 million |
| Gross Profit | $25.3 million | $76.4 million | $31.6 million | $108.0 million |
| Gross Margin | 24.1% | 25.4% | 27.9% | 32.6% |
| Operating Loss | $(9.1) million | $(32.0) million | $1.0 million | $3.6 million |
| Net Loss | $(11.8) million | $(47.3) million | $(1.3) million | $(2.7) million |
| Diluted EPS | $(0.09) | $(0.39) | $(0.01) | $(0.03) |
| Cash & Equivalents (End of Period) | $38.1 million (excluding restricted cash) | |||
| Total Debt (Net) | $145.2 million |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 7% year-over-year for the quarter and 9% for the nine-month period. Product revenue dropped 13% (quarter) and 21% (nine months) due to lower shipment volumes, particularly in China and Asia Pacific. Service revenue remained relatively flat for the quarter but increased 3% for the nine months.
- Margin Compression: Gross margin declined significantly, driven by higher net parts consumption ($3.2 million increase), increased logistics and duties costs, and unfavorable product mix.
- Restructuring Charges: The company incurred $6.5 million in restructuring charges for the quarter and $15.4 million for the nine months, related to a workforce reduction (approximately 15% of global workforce) and asset impairments as part of a transformation plan. No such charges were recorded in the prior year periods.
- Interest Expense Surge: Interest expense increased 192% for the quarter and 177% for the nine months, primarily due to the election of non-cash paid-in-kind (PIK) interest and amortization of debt financing costs and warrant discounts.
- Backlog Reduction: Order backlog decreased to $356.2 million from $452.4 million in the prior year, driven by significant age-outs ($90.3 million) and cancellations ($4.5 million) over the nine-month period.
Guidance, Outlook, and Risks
- Liquidity and Compliance: Management believes current cash resources and debt facilities are sufficient to fund operations for at least the next 12 months. However, the company received a notice from Nasdaq on February 2, 2026, regarding non-compliance with the minimum bid price rule ($1.00 per share). A 180-day compliance period is in effect until August 3, 2026.
- Debt Covenants: The company is subject to financial covenants (fixed charge coverage, leverage ratio, minimum liquidity) under its Amended Financing Agreement. While compliant as of March 31, 2026, management notes uncertainty regarding future compliance due to macroeconomic conditions.
- Geopolitical and Supply Chain Risks: Ongoing conflicts in the Middle East and geopolitical tensions (U.S.-China) continue to impact supply chains, logistics costs, and sales in China. The company expects these headwinds to persist through fiscal year 2026.
- Internal Controls: The company identified two material weaknesses in internal controls over financial reporting as of March 31, 2026, related to footnote disclosure reviews and analysis of information for GAAP presentation. Remediation efforts are underway.
- Tariff Refunds: Following a Supreme Court ruling, the company submitted approximately $9.0 million in tariff refund claims. A participation agreement was entered into to sell these claims for $6.6 million, though recognition of benefits depends on realization.
Investor Verification Checklist
- Nasdaq Compliance: Verify the company's progress in regaining compliance with the $1.00 minimum bid price requirement by the August 3, 2026 deadline to avoid delisting.
- Debt Covenant Status: Monitor future quarterly reports for compliance with the fixed charge coverage and leverage ratios under the Amended Financing Agreement, given the high interest expense and operating losses.
- Restructuring Execution: Track the completion of the FY26 Restructuring Plan (expected completion by June 30, 2026) and the realization of anticipated cost savings.
- China Joint Venture Performance: Assess the impact of geopolitical tensions and tariffs on the China Joint Venture, which represented approximately 16-17% of total net revenue in the recent period.
- Internal Control Remediation: Review updates on the remediation of material weaknesses in internal controls to ensure the reliability of future financial reporting.